Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

150.62
-2.6200-1.71%
Pre-market: 154.804.18+2.78%07:50 EDT
Volume:18.08M
Turnover:2.71B
Market Cap:362.97B
PE:26.01
High:152.71
Open:151.28
Low:147.40
Close:153.24
Loading ...

Johnson & Johnson announces results from Vivacity-MG3 study

TIPRANKS
·
2 hours ago

Johnson & Johnson Says New Data Support Nipocalimab's Long-Term Disease Control in Myasthenia Gravis

MT Newswires Live
·
2 hours ago

Johnson & Johnson assumed with a Buy at Goldman Sachs

TIPRANKS
·
3 hours ago

J&J - up to 128 Weeks & 180 Patient Years of Follow-up in Open-Label Extension(a) Confirm Safety Profile Consistent With Phase 3 Vivacity-Mg3 Study

THOMSON REUTERS
·
4 hours ago

J&J- Results Show 18 Months of Sustained Reduction in Immunoglobulin G Antibodies & Sustained Improvement in Gmg Symptoms

THOMSON REUTERS
·
4 hours ago

Johnson & Johnson Highlights New Data That Showcase the Strength of Nipocalimab, Demonstrating Long-Term Sustained Disease Control in Adults Living With Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS
·
4 hours ago

Johnson & Johnson highlights new data that showcase the strength of nipocalimab, demonstrating long-term sustained disease control in adults living with generalized myasthenia gravis (gMG)

PR Newswire
·
4 hours ago

JNJ, WMT, or AMZN: Which Mega-Cap Stock Is the Best Pick?

TIPRANKS
·
15 hours ago

Lorne Steinberg’s Top Picks for April 7, 2025

Bloomberg
·
18 hours ago

Johnson & Johnson's Janssen Says Subcutaneous Rybrevant Approved for 2 Indications in EU

MT Newswires Live
·
Yesterday

BRIEF-European Commission Approves Johnson & Johnson’S Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen

Reuters
·
Yesterday

European Commission Approves Johnson & Johnson’s Subcutaneous Darzalex® (Daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility

THOMSON REUTERS
·
Yesterday

Shockwave Medical Enrolls First Patient in Forward CAD Pivotal Study of Novel Forward Intravascular Lithotripsy Platform

THOMSON REUTERS
·
Yesterday

Johnson & Johnson Faces Legal Hurdles: Stock Tumbles

TIPRANKS
·
05 Apr

Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits Failure

Zacks
·
04 Apr

Wells Fargo Adjusts Price Target on Johnson & Johnson to $170 From $152, Keeps Equalweight Rating

MT Newswires Live
·
04 Apr

Johnson & Johnson's Tremfya Achieves Key Endpoints in Psoriatic Arthritis Study

MT Newswires Live
·
04 Apr

Johnson & Johnson: Tremfya Phase 3b APEX study achieved primary endpoint

TIPRANKS
·
04 Apr

BRIEF-Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary And Secondary Endpoints

Reuters
·
04 Apr

Johnson & Johnson - Tremfya Phase 3B Study Achieves Primary and Secondary Endpoints

THOMSON REUTERS
·
04 Apr